[{"data":1,"prerenderedAt":101},["ShallowReactive",2],{"article-532":3},{"id":4,"title":5,"articleType":6,"sourceType":7,"sourceKey":8,"securityCode":9,"exchange":10,"exchangeName":11,"createdAt":12,"paragraphs":13,"referenceList":20},532,"APL-2401首例入组≠重大利好：穿透“30日通道”看亚虹医药的真实研发成色","analysis","bulletin","sse_bulletin:11641","688176","sse","上交所",1767862612,[14,15,16,17,18,19],"I期临床首例患者入组，常被市场误读为“重大突破”，但对投资者而言，这不过是创新药漫长征途的第一步。江苏亚虹医药科技股份有限公司（688176.SH）于2026年1月8日公告APL-2401完成I期首例受试者给药，表面看是积极信号，但真正值得追问的是：这一步到底有多快？优势是否真实？公司能否兑现？","首先，“15个工作日完成首例给药”的速度，更多反映的是政策红利而非独家执行力。根据公司公告，APL-2401纳入国家药监局2025年9月推出的“30日通道”，从IND获批到首例给药仅用15个工作日。但该通道要求企业“在获批后12周内启动临床试验”，且试点期间已有项目实现类似效率——如乘典生物CD-001在2025年初也于30天内完成中美双报后的首例给药。这意味着，亚虹的速度并非孤例，而是制度性提速下的行业新常态。","其次，APL-2401宣称的“高选择性FGFR2/3双靶点抑制”确有差异化潜力，但需警惕“纸面优势”。现有上市药物如厄达替尼（erdafitinib）为pan-FGFR抑制剂，易引发高磷血症（FGFR1抑制）和腹泻（FGFR4抑制）。而APL-2401通过非共价结合模式，理论上可规避这些毒性。然而，同类竞品如和誉生物的ABSK061、Incyte公司的INCB126503也主打高选择性，且ABSK061已在I期显示37.5%客观缓解率。真正的胜负手不在机制描述，而在后续剂量探索中能否验证更宽的安全窗与更强的肿瘤抑制活性。","再者，亚虹医药的研发兑现能力仍待验证。公司核心产品APL-2401（用于FGFR2/3驱动的晚期实体瘤）在获批I期临床试验后已成功完成首例受试者入组，但其商业化团队建设尚处早期。过往管线中，多个项目进展缓慢或未披露关键数据，这使得市场对其执行效率存疑。此次APL-2401虽设计了多队列扩展（包括尿路上皮癌、胆管癌等），但I期主要目标仍是评估安全性与最大耐受剂量，同时包含对初步疗效的探索性分析。","值得注意的是，首例受试者在中国入组，说明其国内临床执行体系已能响应“30日通道”节奏，这是积极信号。但创新药的价值锚点从来不是“快”，而是“有效且安全”。当前阶段，APL-2401仅跨过合规门槛，远未证明临床价值。投资者应警惕将政策便利误判为企业护城河，真正需要紧盯的是未来I期剂量爬坡结果及II期试验设计是否聚焦高未满足需求人群。","简言之，这是一次“小步快跑”，而非“弯道超车”。水面之上的公告光鲜，水面之下才是风险与机遇的真正战场。",[21,26,31,35,40,43,47,51,55,59,64,68,72,76,80,84,88,93,97],{"index":22,"title":23,"sourceName":24,"url":25},0,"江苏亚虹医药科技股份有限公司自愿披露关于APL-2401完成I期临床试验首例受试者入组公告","上海证券交易所","https://www.sse.com.cn/disclosure/listedinfo/announcement/c/new/2026-01-09/688176_20260109_VCQY.pdf",{"index":27,"title":28,"sourceName":29,"url":30},1,"亚虹医药：APL-2401完成I期临床试验首例受试者入组","","https://www.nbd.com.cn/articles/2026-01-08/4212209.html",{"index":32,"title":28,"sourceName":33,"url":34},2,"新浪","https://finance.sina.com.cn/roll/2026-01-08/doc-inhfqtyp3782879.shtml",{"index":36,"title":37,"sourceName":38,"url":39},3,"亚虹医药APL-2401获批I期临床试验 适用于晚期实体瘤患者","东方财富","https://finance.eastmoney.com/a/202512173594362454.html",{"index":41,"title":37,"sourceName":29,"url":42},4,"https://stock.10jqka.com.cn/20251217/c673283528.shtml",{"index":44,"title":45,"sourceName":29,"url":46},5,"江苏亚虹医药科技股份有限公司自愿披露关于APL-2401临床试验申请获得国家药品监督管理局批准的公告","https://paper.cnstock.com/html/2025-12/18/content_2159729.htm",{"index":48,"title":49,"sourceName":29,"url":50},6,"创新药临床试验审评审批增设30日通道","https://www.pharmacxo.com/news/detail/7443.html",{"index":52,"title":53,"sourceName":29,"url":54},7,"Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database | Scientific Reports","https://www.nature.com/articles/s41598-025-11411-1",{"index":56,"title":57,"sourceName":29,"url":58},8,"Asieris Received NMPA Approval for IND of APL-2401 to Initiate Phase I Clinical Study in Patients with FGFR2/3-Driven Advanced Solid Tumors - Asieris Pharmaceuticals","https://asieris.com/asieris-received-nmpa-approval-for-ind-of-apl-2401-to-initiate-phase-i-clinical-study-in-patients-with-fgfr2-3-driven-advanced-solid-tumors/",{"index":60,"title":61,"sourceName":62,"url":63},9,"国家药监局发布《关于优化创新药临床试验审评审批有关事项的公告》，创新药临床试验申报进入加速期！","搜狐","https://www.sohu.com/a/936425960_122502738",{"index":65,"title":66,"sourceName":62,"url":67},10,"FGFR抑制剂ASN-8639片治疗FGFR2/3基因改变实体瘤患者_参与者_评估_标准","https://www.sohu.com/a/969774971_100169898",{"index":69,"title":70,"sourceName":29,"url":71},11,"Discovery of Orally Bioavailable FGFR2/FGFR3 Dual Inhibitors via Structure-Guided Scaffold Repurposing Approach","https://pmc.ncbi.nlm.nih.gov/articles/PMC10009791/",{"index":73,"title":74,"sourceName":33,"url":75},12,"创新药临床试验审评再提速 国家药监局推出“30日通道”","https://finance.sina.com.cn/roll/2025-09-12/doc-infqfhcp2931052.shtml",{"index":77,"title":78,"sourceName":29,"url":79},13,"Discovery and Development of INCB126503: A Potent and Selective FGFR2/3 Inhibitor","https://www.thieme-connect.com/products/ejournals/html/10.1055/a-2639-3321",{"index":81,"title":82,"sourceName":29,"url":83},14,"临床试验审评审批新规：国家药监局设30日创新药审评通道，加速新药研发！","https://www.pharnexcloud.com/zixun/zc_56322",{"index":85,"title":86,"sourceName":29,"url":87},15,"乘典生物：30天内从中国IND默许推进到完成首例患者给药，背后的关键策略是什么？医药新闻-ByDrug-一站式医药资源共享中心-医药魔方","https://bydrug.pharmcube.com/news/detail/d1ea865d6797ce579a7251adfe529c4e",{"index":89,"title":90,"sourceName":91,"url":92},16,"创新药临床试验审批再提速！国家药监局开通“30日通道”","百度","https://health.baidu.com/m/detail/ar_9048360790854963733",{"index":94,"title":95,"sourceName":62,"url":96},17,"FGFR2/3抑制剂ABSK061在晚期实体瘤中显示出安全性和初步疗效","https://www.sohu.com/a/764000119_121797544",{"index":98,"title":99,"sourceName":91,"url":100},18,"FGFR2/3抑制剂ABSK061治疗实体瘤首次人体临床研究数据出炉！","https://m.baidu.com/bh/m/detail/ar_9261805658909178099",1767862999360]